- Home
- ACM vs DVA Comparison
ACM vs DVA Comparison
Compare ACM & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- DVA
- Stock Information
- Founded
- ACM 1980
- DVA 1994
- Country
- ACM United States
- DVA United States
- Employees
- ACM N/A
- DVA N/A
- Industry
- ACM Military/Government/Technical
- DVA Misc Health and Biotechnology Services
- Sector
- ACM Consumer Discretionary
- DVA Health Care
- Exchange
- ACM Nasdaq
- DVA Nasdaq
- Market Cap
- ACM 15.4B
- DVA 12.6B
- IPO Year
- ACM 2007
- DVA 1995
- Fundamental
- Price
- ACM $106.95
- DVA $149.77
- Analyst Decision
- ACM Strong Buy
- DVA Hold
- Analyst Count
- ACM 8
- DVA 5
- Target Price
- ACM $119.38
- DVA $153.40
- AVG Volume (30 Days)
- ACM 826.6K
- DVA 658.8K
- Earning Date
- ACM 02-03-2025
- DVA 02-11-2025
- Dividend Yield
- ACM 0.86%
- DVA N/A
- EPS Growth
- ACM 655.22
- DVA 41.03
- EPS
- ACM 2.95
- DVA 9.24
- Revenue
- ACM $16,105,498,000.00
- DVA $12,666,614,000.00
- Revenue This Year
- ACM $6.98
- DVA $6.17
- Revenue Next Year
- ACM $5.22
- DVA $3.56
- P/E Ratio
- ACM $36.24
- DVA $16.13
- Revenue Growth
- ACM 12.01
- DVA 6.34
- 52 Week Low
- ACM $82.23
- DVA $103.40
- 52 Week High
- ACM $118.56
- DVA $169.52
- Technical
- Relative Strength Index (RSI)
- ACM 33.23
- DVA 38.07
- Support Level
- ACM $110.87
- DVA $145.14
- Resistance Level
- ACM $113.82
- DVA $156.74
- Average True Range (ATR)
- ACM 1.79
- DVA 3.44
- MACD
- ACM -0.98
- DVA -1.65
- Stochastic Oscillator
- ACM 1.38
- DVA 21.28
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.